首页> 外国专利> COMPOSITION CONTAINING DIAMINOXIDASE FOR USE FOR TREATMENT OR PREVENTION OF FIBROMIALGIA OR CHRONIC FATIGUE SYNDROME

COMPOSITION CONTAINING DIAMINOXIDASE FOR USE FOR TREATMENT OR PREVENTION OF FIBROMIALGIA OR CHRONIC FATIGUE SYNDROME

机译:包含二胺氧化酶的组合物,用于治疗或预防纤维炎或慢性疲劳综合征

摘要

1. The use of diaminoxidase (DAO) to obtain a composition for the prevention or treatment of fibromyalgia or chronic fatigue syndrome. 2. The use according to claim 1, characterized in that the DAO is administered orally in the form of tablets, capsules or sachets. The use according to claim 1, characterized in that the DAO is administered in a dose of from 0.1 to 50 mg. The use according to claim 2, characterized in that the DAO is administered in a dose of from 0.1 to 50 mg. The use according to any one of claims 1 to 4, characterized in that said composition further comprises caffeine. The use according to claim 5, characterized in that the caffeine is administered in a dose of from 1 to 100 mg. The use according to any one of claims 1 to 4 or 6, characterized in that said dosage forms are protected from the effects of the stomach environment. The use according to claim 5, characterized in that said dosage forms are protected from the effects of the stomach environment. The use according to any one of claims 1 to 4, 6 or 8, characterized in that the DAO is used in free form, in the form of a powder, lyophilized powder, microcapsules, nanocapsules or liposomes. 10. The use according to claim 5, characterized in that the DAO is used in free form, in the form of a powder, lyophilized powder, microcapsules, nanocapsules or liposomes. The use according to claim 7, characterized in that the DAO is used in free form, in the form of a powder, lyophilized powder, microcapsules, nanocapsules or liposomes.
机译:1.二氨氧化酶(DAO)用于获得预防或治疗纤维肌痛或慢性疲劳综合症的组合物的用途。 2.根据权利要求1的用途,其特征在于所述DAO以片剂,胶囊剂或小囊剂的形式口服给药。 2.根据权利要求1的用途,其特征在于DAO以0.1至50mg的剂量施用。 3.根据权利要求2的用途,其特征在于DAO以0.1至50mg的剂量施用。 5.根据权利要求1-4中任一项的用途,其特征在于所述组合物还包含咖啡因。 6.根据权利要求5的用途,其特征在于咖啡因的剂量为1至100mg。 7.根据权利要求1至4或6中任一项的用途,其特征在于所述剂型被保护免受胃环境的影响。 6.根据权利要求5的用途,其特征在于保护所述剂型不受胃环境的影响。 9.根据权利要求1-4、6或8中任一项的用途,其特征在于所述DAO以粉末,冻干粉末,微胶囊,纳米胶囊或脂质体形式的游离形式使用。 10.根据权利要求5的用途,其特征在于DAO以粉末,冻干粉末,微胶囊,纳米胶囊或脂质体的形式以游离形式使用。 8.根据权利要求7所述的用途,其特征在于,所述DAO以粉末,冻干粉末,微胶囊,纳米胶囊或脂质体形式的游离形式使用。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号